Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C18H19N3O4
CAS Number:
Molecular Weight:
341.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
solubility
DMSO: ≥6.0 mg/mL (Warmed), H2O: insoluble
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES string
CCOC(=O)c1ncn2-c3ccc(OC)cc3C(=O)N4CCCC4c12
InChI
1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1
InChI key
YKYOQIXTECBVBB-AWEZNQCLSA-N
Gene Information
human ... GABRA5(2558)
Application
L-655,708 has been used as an α5 GABAA receptor inverse agonist to inhibit the discriminative stimulus of propofol in a dose-dependent manner.
Biochem/physiol Actions
L-655,708 is an inverse agonist of the α5 γ-Aminobutyric acid type A (GABAA) receptor. It has an ability to increase cognition in rats.
Ligand for benzodiazepine site of GABAA receptors containing α5 subunits.
Novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit.
Features and Benefits
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
DISCOVER Bioactive Small Molecules for Neuroscience
Flavia R Carreno et al.
The international journal of neuropsychopharmacology, 20(6), 504-509 (2017-03-25)
Selective augmentation of hippocampal activity in ways similar to that caused by ketamine may have therapeutic advantages over ketamine, which has psychotomimetic and reinforcing effects likely due to effects outside the hippocampus (i.e., off-target effects). Here we evaluated the antidepressant-like
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors
Atack JR, et al.
Neuropharmacology, 51(6), 1023-1029 (2006)
Jonathan Fischell et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(11), 2499-2509 (2015-04-23)
Selective serotonin reuptake inhibitors (SSRIs) are the primary pharmacological treatment for depression, but SSRIs are effective in only half of the patients and typically take several weeks to relieve symptoms. The NMDA receptor antagonist ketamine exerts a rapid antidepressant action
Global Trade Item Number
| SKU | GTIN |
|---|---|
| L9787-5MG | 04061832557052 |
| L9787-25MG | 04061832557045 |